Baby Safety / Compounds / Psilocybin

Is Psilocybin safe for babies and kids?

Elevated risk for kids

Infants are more vulnerable to Psilocybin than children or adults due to immature hepatic/renal clearance, higher intake-to-body-weight ratio, rapid organ development, and increased gastrointestinal absorption.

What is psilocybin?

The IUPAC name is [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate.

Also known as: [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate, Psilocybine, Indocybin, Psilocibin.

IUPAC name
[3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate
CAS number
520-52-5
Molecular formula
C12H17N2O4P
Molecular weight
284.25 g/mol
SMILES
CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O
PubChem CID
10624

Risk for babies

Elevated risk

Infants are more vulnerable to Psilocybin than children or adults due to immature hepatic/renal clearance, higher intake-to-body-weight ratio, rapid organ development, and increased gastrointestinal absorption.

Neonates and infants up to 12 months have incomplete blood-brain barrier development, immature Phase I/II metabolic enzymes (particularly CYP3A4, UGT1A1), and higher gastrointestinal permeability. Equivalent doses produce higher internal concentrations and longer residence times.

What to do: Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

Risk for pregnant and nursing people

Context-dependent

Pregnancy alters the metabolism and distribution of Psilocybin, potentially increasing fetal exposure. The developing embryo/fetus is vulnerable during organogenesis (weeks 3-8) and neurological development. Placental transfer should be assumed.

No specific reproductive toxicity data identified, but pregnancy-specific safety data is limited for most chemicals. Precautionary minimization of exposure is recommended.

What to do: Minimize exposure during pregnancy and lactation. Consult healthcare provider regarding specific risks. Consider alternative products with lower hazard profiles.

Regulatory consensus

2 regulatory and scientific bodies have classified Psilocybin. The classifications differ — that's the data.

AgencyYearClassificationNotes
DEA—Schedule IControlled substance classification
FDA—Breakthrough Therapy designationFor major depressive disorder and treatment-resistant depression

Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.

Where kids encounter psilocybin

  • Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
  • Occupational Environments — Factories, Warehouses, Transportation vehicles

Safer alternatives

Lower-risk approaches that achieve a similar outcome to Psilocybin:

  • Cessation / treatment programs
    Trade-offs: Removes 95-99% of dissolved contaminants including metals, PFAS, nitrates; wastes 2-4 gallons per gallon produced (improving with newer systems); removes beneficial minerals; $0.05-0.25/gallon; requires pre-treatment for longevity.
    Relative cost: 1.2-2×

Frequently asked questions

Is psilocybin safe for kids?

Infants are more vulnerable to Psilocybin than children or adults due to immature hepatic/renal clearance, higher intake-to-body-weight ratio, rapid organ development, and increased gastrointestinal absorption.

What products contain psilocybin?

Psilocybin appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).

What should I do if my child is exposed to psilocybin?

Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

See Psilocybin in the baby app

Look up products containing psilocybin, compare to alternatives, and explore the full data record.

Open in baby View raw API data

Sources (2)
  1. US DEA: Psilocybin and Psilocin — Schedule I Classification, FDA Breakthrough Therapy Designations (Depression), Oregon and Colorado Regulatory Frameworks, Australia Therapeutic Authorization (2023), and Mushroom Misidentification with Galerina (2023) (2023) — regulatory
  2. Carhart-Harris R, Goodwin GM: The Therapeutic Potential of Psychedelic Drugs — Psilocybin 5-HT2A Mechanism, Clinical Trial Efficacy Data (TRD and MDD), Physiological Safety Profile, Risk-Benefit at Therapeutic Doses, and Adolescent Brain Development Considerations (Neuropsychopharmacology, 2017; updated 2023) (2023) — academic

Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →